Research Reports | Market Assessment
September 2016

Gastrointestinal Stromal Tumor, Malignant Melanoma, Renal Cell Carcinoma | Access and Reimbursement | EU5 | 2016

The success of an anticancer therapy is not only dependent on the outcome of its pivotal trial, but also on that trial’s design, which is examined by the regulatory bodies, payers, and prescribers. In our analysis, we assess the influence of trial design on treatment and reimbursement decisions regarding current and emerging therapies for malignant melanoma, renal cell carcinoma (RCC), and gastrointestinal stromal tumors (GIST). In addition, we explore payers’ and prescribers’ cost-sensitivity and preference for trial design features, such as primary end points and comparators.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports